From Research to Innovation: Two Biotech Startups Launched with PARCC’s Support

The PARCC is proud to announce its recent contribution to the creation of two promising biotech startups. This milestone illustrates the strength of our academic research and its ability to transform into concrete medical solutions for patients.

🔬 DETERA Therapeutics

• Field: Rare renal diseases (adults and children).

• Mission: Developing a pipeline of “First-In-Class” therapies for rare kidney diseases with high unmet medical needs.

• Key Innovation:

  • DTR8: A First-In-Class drug candidate targeting extracapillary glomerulonephritis (CGN).

  • Local, specific, and immediate renal therapy.

  • Coupled with a companion diagnostic test.

• Expected Impact: Preserving renal function, halting disease progression, and reducing the need for dialysis.

• PARCC Member: Pierre-Louis Tharaux.

• Learn more: detera-therapeutics.com

🧠 D2B3

• Field: Drug delivery to the brain and Central Nervous System (CNS).

• Mission: Revolutionizing therapeutic access to the brain to treat complex CNS disorders.

• Key Innovation:

  • Proprietary technology enabling the transient and targeted opening of the blood-brain barrier.

  • A “plug-and-play” approach, compatible with most drugs and therapeutic classes.

• Expected Impact: Significantly improving the efficacy of treatments for numerous CNS pathologies.

• PARCC Members: Kevin Boye and Anne Eichmann.

• Learn more: d2b3.bio